

## SEQUENCE LISTING

<110> MIZUGUCHI, HIROYUKI  
HAYAKAWA, TAKAO

<120> ADENOVIRUS VECTOR

<130> 081356/0163

<140> 09/845,160  
<141> 2001-05-01

<150> JP 2001-131688  
<151> 2001-04-27

<150> JP 2000-161577  
<151> 2000-05-31

<160> 14

<170> PatentIn Ver. 2.1

<210> 1  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide having affinity with heparan sulfate.

<400> 1

Lys Lys Lys Lys Lys Lys Lys  
1 5

<210> 2

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Peptide having affinity with laminin receptor.

<400> 2

Thr Ser Gly Tyr Ile Gly Ser Arg Gly Tyr Ile Gly Ser Arg Gly Tyr  
1 5 10 15

Ile Gly Ser Arg Ser Ser  
20

<210> 3

<211> 16

<212> PRT

<213> Artificial Sequence



&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Peptide having affinity with laminin receptor.

&lt;400&gt; 3

Thr Ser Ala Ala Ser Ile Lys Val Ala Val Ser Ile Lys Val Ala Val  
1 5 10 15

&lt;210&gt; 4

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Peptide having affinity with E-selectin.

&lt;400&gt; 4

Thr Arg Ser Asp Ile Thr Trp Asp Gln Leu Trp Asp Leu Met Lys Thr  
1 5 10 15  
Ser

&lt;210&gt; 5

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: RGD-4C peptide.

&lt;400&gt; 5

Cys Asp Cys Arg Gly Asp Cys Phe Cys  
1 5

&lt;210&gt; 6

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: NGR associating peptide.

&lt;400&gt; 6

Cys Asn Gly Arg Cys Val Ser Gly Cys Ala Gly Arg Cys  
1 5 10

&lt;210&gt; 7

&lt;211&gt; 81

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Oligonucleotide 1.

<400> 7  
aacaggagac acaacttcga acatcgatcc aagtgcatac tctatgtcat tttcatggga 60  
ctggtctggc cacaactaca t 81

<210> 8  
<211> 79  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Oligonucleotide 2.

<400> 8  
taatgttagtt gtggccagac cagtcggatg aaaatgacat agagtatgca cttggatcga 60  
tggtcgaaat tgtgtctcc 79

<210> 9  
<211> 10  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Oligonucleotide 3.

<400> 9  
cggttaattaa 10

<210> 10  
<211> 31  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Oligonucleotide 4.

<220>  
<221> CDS  
<222> (3)...(29)

<400> 10  
cg aag tgt gac tgc cgc gga gac tgt ttc tg 31  
Lys Cys Asp Cys Arg Gly Asp Cys Phe Cys  
1 5 10

<210> 11  
<211> 31  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Oligonucleotide 5.

<400> 11  
cgccagaaaca gtctccgcgg cagtcacact t 31

<210> 12  
<211> 42  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Oligonucleotide 6.

<400> 12  
cggtgcggcggctgctgatccggccgc tg

42

<210> 13  
<211> 42  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Oligonucleotide 7.

<400> 13  
cgccggccggccggccggccggccggccgc tg

42

<210> 14  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic peptide

<400> 14  
Lys Cys Asp Cys Arg Gly Asp Cys Phe Cys  
1 5 10